Physicians' Academy for Cardiovascular Education

Atherosclerosis

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Harmful effects of alcohol and smoking on arterial system in adolescents

3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Lipoprotein metabolism & CV risk: a long road from understanding to treatment

10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

Analogous to LDL-c, the lower the better also seems true for inflammation

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Hb1Ac associated with subclinical atherosclerosis in individuals without diabetes

Literature - July 5, 2021 - Rossello X,, et al. - J Am Coll Cardiol

This study using data of PESA demonstrated that HbA1c levels are associated with risk for subclinical atherosclerosis in low-risk individuals without diabetes, even at levels below the prediabetes threshold.

Two-thirds of ASCVD patients in the US do not reach LDL-c <70 mg/dL after 2 years on LLT

Literature - June 30, 2021 - Cannon CP et al. - JAMA Cardiol. 2021

This prospective registry study in the US showed that only 17.1% of patients with ASCVD on LLT had their therapy intensified over the next 2 years. Only 31.7% of patients achieved LDL-c levels <70mg/dL at 2 years.

Icosapent ethyl reduces whole-heart coronary atherosclerotic plaque burden

News - May 31, 2021

ACC 2021 This subanalysis of the EVAPORATE trial showed a significant reduction in whole-heart atherosclerotic plaque burden over 18 months in statin-treated patients with elevated triglyceride levels who received icosapent ethyl compared to those on placebo.

Elevated markers of atherosclerosis and lower carotid distensibility associated with dementia

Literature - May 5, 2021 - Wang W et al. - J Am Heart Assoc. 2021

This analysis in a community-based cohort showed that elevated carotid intima-media thickness and interadventitial diameter and lower carotid distensibility were associated with increased risk of incident dementia.

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Literature - Apr. 20, 2021 - Wright RS et al. - J Am Coll Cardiol. 2021

This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.

People aged 70-100 years with elevated LDL-c are at high risk of MI and ASCVD

Literature - Jan. 21, 2021 - Mortensen MB & Nordestgaard BG., - Lancet. 2020

In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age. NNT to prevent one MI or ASCVD event was lower in people aged 70-100 years compared to younger individuals.

Silent CAD present in 4 out of 10 Swedish individuals

News - Nov. 14, 2020

AHA 2020 Prevalence of CAD in a Swedish population was 4 out of 10, using CCTA data from the SCAPIS cohort. A prediction model was developed to identify those with widespread atherosclerosis.

A marriage of clinical trial results and imaging findings with icosapent ethyl

Results of the EVAPORATE trial

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD
Three experts discuss detailed findings of the EVAPORATE study and how to interpret these. THe EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Three experts discuss the findings of the EVAPORATE study in detail and how to interpret these. The EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Elevated Lp(a) and family history of CHD have independent and additive joint associations with CV events

Literature - Sep. 7, 2020 - Mehta A et al., - J Am Coll Cardiol. 2020.

This study evaluated the independent and joint associations of elevated Lp(a) and family history of CHD with incident ASCVD and CHD events among asymptomatic subjects.

Similar risk for ASCVD in PAD patients compared to those with CHD or cerebrovascular disease

Literature - Aug. 19, 2020 - Colantonio LD, et al. - J Am Coll Cardiol 2020

ASCVD event rate in PAD patients is similar as that in CHD patients, yet statin therapy was lower in PAD patients.

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD
 Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.

Prof. Klaus Parhofer discusses the role of hypertriglyceridemia in the setting of residual risk.